Table 2 Lymphoma entities

All lymphomas

521

74%

66%

56%

82%

76%

70%

64%

52%

42%

 Primary aggressive B-cell lymphomas

121

59%

53%

47%

67%

64%

56%

52%

45%

41%

  DLBCL or high-grade B-cell lymphoma

105

59%

52%

44%

68%

64%

55%

50%

42%

38%

  Not-DLBCL or high-grade B-cell lymphoma

16

60%

60%

60%

0.28

64%

64%

64%

0.55

61%

61%

61%

0.14

   FL grade 3B

2

   Burkitt lymphoma

3

   PTLD

2

   PMBCL or greyzone lymphoma

3

   Plasmablastic lymphoma

5

   Lymphomatoid granulomatosis grade III

1

 Upfront patients

7

86%

86%

86%

100%

100%

100%

86%

86%

86%

  Relapsed/refractory patients

114

58%

51%

44%

0.19

65%

62%

53%

0.070

50%

43%

38%

0.09

 Transformed B-cell lymphomas

107

71%

63%

52%

78%

69%

64%

59%

42%

35%

  Transformed FL

72

76%

71%

56%

81%

75%

68%

65%

48%

38%

  Transformed not-FL

35

61%

41%

41%

0.22

73%

49%

49%

0.35

48%

30%

30%

0.28

   Transformed MZL

18

   Transformed CLL/SLL (Richter)

5

   Transformed WM

3

   Transformed NLPHL

2

   Transformed indolent B-cell lymphoma

7

  Upfront patients

28

92%

92%

92%

95%

95%

95

68%

55%

41%

  Relapsed/refractory patients

79

64%

54%

41%

0.006

73%

61%

55%

0.009

55%

38%

33%

0.13

  Primary and transformed aggressive B-cell lymphomas

228

64%

58%

50%

72%

67%

60%

55%

44%

39%

   Upfront patients

35

90%

90%

90%

96%

96%

96%

72%

63%

54%

   Relapsed/refractory patients

193

60%

53%

44%

0.002

68%

63%

54%

0.001

52%

42%

37%

0.028

 Indolent B-cell lymphomas

49

80%

59%

44%

90%

75%

65%

60%

45%

26%

  FL grade 1-3A

39

78%

57%

43%

88%

76%

69%

60%

44%

31%

  Not-FL grade 1-3A

10

89%

63%

51%

0.55

100%

71%

57%

0.24

57%

46%

11%

0.48

   MZL

1

   CLL/SLL

6

   WM

1

   NLPHL

2

  All indolent lymphomas

156

74%

61%

48%

82%

71%

64%

59%

43%

31%

   Not transformed

49

80%

59%

44%

90%

75%

65%

60%

45%

26%

   Transformed

107

71%

63%

52%

0.77

78%

69%

64%

0.65

59%

42%

35%

0.77

  All follicular lymphomas

111

77%

65%

50%

83%

75%

68%

63%

47%

35%

   Not transformed

39

78%

57%

43%

88%

76%

69%

60%

44%

31%

   Transformed

72

76%

71%

56%

0.58

81%

75%

68%

0.63

65%

48%

38%

0.69

 Mantle cell lymphoma

99

86%

75%

73%

91%

82%

82%

80%

62%

43%

  Classical

83

90%

78%

78%

95%

86%

86%

84%

67%

47%

   Non-classical

16

66%

58%

43%

0.021

70%

62%

62%

0.025

61%

37%

18%

0.005

   Blastic

9

   Pleomorphic or P53+ or Ki67 > 60%

7

  Upfront patients

87

90%

78%

78%

93%

84%

84%

83%

66%

45%

  Relapsed/refractory patients

12

58%

49%

32%

0.006

81%

67%

67%

0.30

58%

40%

40%

0.054

 T-cell lymphomas

85

74%

69%

53%

83%

79%

71%

65%

54%

45%

  PTCL

78

79%

73%

56%

87%

83%

74%

70%

58%

48%

  Non-PTCL

7

18%

18%

ND

0.004

25%

25%

ND

0.013

0%

0%

0%

0.002

   Sézary/ATLL

3

   ENKTCL

4

   PTCL, ALCL

25

79%

79%

74%

91%

91%

91%

80%

75%

70%

   PTCL, non-ALCL

53

78%

69%

41%

0.08

85%

78%

63%

0.09

65%

47%

33%

0.023

   AITL/FHTCL

29

   PTCL-NOS

17

   EATCL/HSTCL/SPTCL/Lennert

7

   Upfront PTCL patients

56

81%

75%

67%

86%

80%

71%

70%

60%

55%

   Relapsed/refractory PTCL patients

22

73%

68%

39%

0.07

89%

89%

80%

0.44

68%

54%

38%

0.21

 Classical Hodgkin lymphoma

60

85%

83%

74%

92%

90%

90%

71%

66%

60%